AbbVie - ABBV Stock Forecast, Price & News

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABBV shares.
View ABBV analyst ratings or view top-rated stocks.

16 Wall Street analysts have issued 12 month target prices for AbbVie's stock. Their ABBV share price forecasts range from $135.00 to $200.00. On average, they predict the company's stock price to reach $159.35 in the next twelve months. This suggests a possible upside of 12.8% from the stock's current price.
View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts.

AbbVie's stock was trading at $135.40 at the beginning of 2022. Since then, ABBV shares have increased by 4.3% and is now trading at $141.21.
View the best growth stocks for 2022 here.

AbbVie saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 11,380,000 shares, a decrease of 12.5% from the August 15th total of 13,010,000 shares. Based on an average trading volume of 5,520,000 shares, the short-interest ratio is presently 2.1 days.
View AbbVie's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our ABBV earnings forecast.

AbbVie Inc. (NYSE:ABBV) announced its earnings results on Friday, July, 29th. The company reported $3.51 earnings per share for the quarter, topping analysts' consensus estimates of $3.42 by $0.09. The business had revenue of $14.58 billion for the quarter, compared to the consensus estimate of $14.64 billion. AbbVie had a trailing twelve-month return on equity of 158.41% and a net margin of 22.03%. The company's quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the company posted $3.11 earnings per share.
Read the conference call transcript.

AbbVie declared a quarterly dividend on Friday, September 9th. Stockholders of record on Friday, October 14th will be given a dividend of $1.41 per share on Tuesday, November 15th. This represents a $5.64 annualized dividend and a dividend yield of 3.99%. The ex-dividend date of this dividend is Thursday, October 13th.
Read our dividend analysis for ABBV.

AbbVie (NYSE:ABBV) pays an annual dividend of $5.64 per share and currently has a dividend yield of 3.94%. The company has been increasing its dividend for 50 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 79.89%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 47.80% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

AbbVie issued an update on its third quarter 2022 earnings guidance on Monday, August, 8th. The company provided earnings per share guidance of $3.55-$3.59 for the period, compared to the consensus estimate of $3.67. The company issued revenue guidance of $14.80 billion-$14.80 billion, compared to the consensus revenue estimate of $15.28 billion.

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX).

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie's stock is owned by many different institutional and retail investors. Top institutional investors include State Street Corp (4.36%), Price T Rowe Associates Inc. MD (1.74%), Northern Trust Corp (1.25%), FMR LLC (0.98%), Franklin Resources Inc. (0.73%) and Legal & General Group Plc (0.71%). Insiders that own company stock include Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Edward J Rapp, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and Timothy J Richmond.
View institutional ownership trends.

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABBV stock can currently be purchased for approximately $141.21.

AbbVie (NYSE:ABBV) has a market capitalization of $249.67 billion and generates $56.20 billion in revenue each year. The company earns $11.54 billion in net income (profit) each year or $7.06 on an earnings per share basis.

The company employs 50,000 workers across the globe.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The official website for the company is www.abbvie.com. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.